Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanu Modi

Showing results (51-60 of 115) with videos related to

Pageof 12
Sort By:
Cornea|November 28, 2021
Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug ConjugatesJulia Canestraro, Malin Hultcrantz, Shanu Modi, et al.
The Lancet. Oncology|May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 studyKohei Shitara, Hiroji Iwata, Shunji Takahashi, et al.
JAMA Dermatology|March 7, 2019
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy AlopeciaAzael Freites-Martinez, Donald Chan, Vincent Sibaud, et al.
Expert Opinion on Investigational Drugs|March 28, 2014
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsKomal Jhaveri, Stefan O Ochiana, Mark Ps Dunphy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineIan E Krop, Patricia LoRusso, Kathy D Miller, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|May 13, 2016
Copper-64 trastuzumab PET imaging: a reproducibility studyJorge A Carrasquillo, Patrick G Morris, John L Humm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i>-Mutated HER2-Positive Metastatic Breast CancerKomal Jhaveri, Joshua Z Drago, Payal Deepak Shah, et al.
Cancer Investigation|October 6, 2005
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancerShanu Modi, Michael P DiGiovanna, Zhao Lu, et al.
Clinical Breast Cancer|January 5, 2016
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 InhibitorsKomal Jhaveri, Sarat Chandarlapaty, Neil Iyengar, et al.
Clinical Breast Cancer|May 19, 2005
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxaneShanu Modi, Violante E Currie, Andrew D Seidman, et al.
Pageof 12

Showing results (51-60 of 115) with videos related to

Sort By:
Pageof 12
Cornea|November 28, 2021
Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug ConjugatesJulia Canestraro, Malin Hultcrantz, Shanu Modi, et al.
The Lancet. Oncology|May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 studyKohei Shitara, Hiroji Iwata, Shunji Takahashi, et al.
JAMA Dermatology|March 7, 2019
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy AlopeciaAzael Freites-Martinez, Donald Chan, Vincent Sibaud, et al.
Expert Opinion on Investigational Drugs|March 28, 2014
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsKomal Jhaveri, Stefan O Ochiana, Mark Ps Dunphy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineIan E Krop, Patricia LoRusso, Kathy D Miller, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|May 13, 2016
Copper-64 trastuzumab PET imaging: a reproducibility studyJorge A Carrasquillo, Patrick G Morris, John L Humm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i>-Mutated HER2-Positive Metastatic Breast CancerKomal Jhaveri, Joshua Z Drago, Payal Deepak Shah, et al.
Cancer Investigation|October 6, 2005
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancerShanu Modi, Michael P DiGiovanna, Zhao Lu, et al.
Clinical Breast Cancer|January 5, 2016
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 InhibitorsKomal Jhaveri, Sarat Chandarlapaty, Neil Iyengar, et al.
Clinical Breast Cancer|May 19, 2005
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxaneShanu Modi, Violante E Currie, Andrew D Seidman, et al.
Pageof 12